We Report, You Decide

WHO Discontinues Trial Of Hydroxychloroquine, Lopinavir/Ritonavir For Covid-19 Treatment

Geneva: The World Health Organization (WHO) announced on Saturday that it was discontinuing hydroxychloroquine and lopinavir/ritonavir arms for its Solidarity Trial, citing little or no reduction in the mortality of hospitalised Covid-19 patients.

The WHO said the decision was in light of the evidence from the Solidarity Trial interim results.

“These interim trial results show that hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalized Covid-19 patients when compared to standard of care. Solidarity trial investigators will interrupt the trials with immediate effect,” the WHO said in a press release, Xinhua reported.

But the organization said this decision applies only to hospitalized patients and does not affect the possible evaluation in other studies of hydroxychloroquine or lopinavir/ritonavir in non-hospitalised patients or as pre- or post-exposure prophylaxis for Covid-19.

The Solidarity Trial was established by the WHO in March to find an effective Covid-19 treatment for hospitalised patients. It was originally designed to have five trial arms, including standard or usual care provided to Covid-19 patients, remdesivir, lopinavir/ritonavir combined, lopinavir/ritonavir combined with interferon beta, and hydroxychloroquine or chloroquine.

- Advertisement -

By enrolling patients in multiple countries, the Solidarity Trial aims to rapidly discover whether any of the drugs slow disease progression or improve survival.


Read More:

Covid-19: WHO Team To Visit China Next Week To Investigate Source Of SARS-Cov-2

WHO Says AstraZeneca, Modena Leading Vaccine Race

Read Our Next Story

End Google Tag Manager (noscript)